The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. The drug,

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot nearly eliminated new infections in people at high risk of HIV.